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Abstract
Factors known to affect melanoma survival include age at presentation, sex and tumor characteristics. Polymorphisms 
also appear to modulate survival following diagnosis. Result from other studies suggest that vitamin D receptor (VDR) 
polymorphisms (SNPs) impact survival in patients with glioma, renal cell carcinoma, lung, breast, prostate and other cancers; 
however, a comprehensive study of VDR polymorphisms and melanoma-specific survival is lacking. We aimed to investigate 
whether VDR genetic variation influences survival in patients with cutaneous melanoma. The analysis involved 3566 
incident single and multiple primary melanoma cases enrolled in the international population-based Genes, Environment, 
and Melanoma Study. Melanoma-specific survival outcomes were calculated for each of 38 VDR SNPs using a competing 
risk analysis after adjustment for covariates. There were 254 (7.1%) deaths due to melanoma during the median 7.6 years 
follow-up period. VDR SNPs rs7299460, rs3782905, rs2239182, rs12370156, rs2238140, rs7305032, rs1544410 (BsmI) and rs731236 
(TaqI) each had a statistically significant (trend P values < 0.05) association with melanoma-specific survival in multivariate 
analysis. One functional SNP (rs2239182) remained significant after adjustment for multiple testing using the Monte Carlo 
method. None of the SNPs associated with survival were significantly associated with Breslow thickness, ulceration or 
mitosis. These results suggest that the VDR gene may influence survival from melanoma, although the mechanism by which 
VDR exerts its effect does not seem driven by tumor aggressiveness. Further investigations are needed to confirm our results 
and to understand the relationship between VDR and survival in the combined context of tumor and host characteristics.
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Introduction
The 5-year survival rate of melanoma ranges from 98% for local-
ized disease to <20% in patients with distant metastases at the 
time of diagnosis (1,2). Factors known to affect progression and 
survival include age at presentation; sex (3–5); anatomic site 
of the tumor (6); primary tumor characteristics, such as tumor 
thickness, presence of ulceration and presence of mitoses; and 
presence or absence of nodal or distant metastases at the time 
of diagnosis (7). In addition, host genetic factors also appear to 
have an effect on outcome (8–14).
The major circulating form of vitamin D, 25-hydroxyvita-
min D, is inversely related to incidence and mortality of several 
cancers, including colorectal, lung, breast and prostate cancer 
(15–28). In support of its potential tumor-suppressor action, this 
hormone has been shown to suppress cell adhesion and migra-
tion (29,30), induce apoptosis (31) and suppress growth of mela-
noma cells in vitro and in xenografts (30,32–34). Observational 
studies have also suggested that vitamin D and its putative 
surrogates, such as season, geographic latitude and evidence of 
continuous sun exposure, are associated with more favorable 
outcomes in individuals with melanoma, despite the fact that 
exposure to ultraviolet radiation, which activates the precursor 
of vitamin D present in skin, increases the risk for developing 
melanoma (6,35–37).
The biologically active form of Vitamin D, 1,25-dihydroxy-
vitamin D, exerts its effects through binding to the nuclear 
Vitamin D receptor (VDR), which in turn regulates the tran-
scription of many other genes. VDR expression is decreased in 
several advanced solid tumors, and higher VDR expression has 
been associated with better survival in patients with lung (38,39) 
and breast cancer (40,41). In melanoma, VDR expression was 
lower in tumors relative to that in nevi or normal skin, with a 
marked reduction of expression in vertical versus radial growth 
phases (42). VDR expression has also been inversely associated 
with tumor progression (43), indicating that VDR signaling path-
way may be relevant in preventing melanocytic progression. 
VDR expression and function can be modified by epigenetic and 
genetic changes (44,45).
The VDR gene contains numerous variants, some of which 
are hypothesized to influence the expression, stability or down-
stream transactivation by the translated protein. Only a few 
common polymorphisms in the VDR gene have been included 
in most studies to date, and reports suggest that some variants 
might modify disease-specific outcomes in patients with breast 
cancer (46), lung cancer (47,48), renal cell carcinoma (49), ovar-
ian cancer (50), prostate cancer (51,52), head and neck cancers 
(53,54), colorectal cancer (26) and glioma (55); however, oth-
ers reported no effect (56–58). In melanoma patients, Newton-
Bishop et al. (36) investigated the VDR variants Cdx-2, GATA, FokI, 
BsmI, ApaI and TaqI in a cohort of 872 cases and found no main 
effect on overall survival, although the authors concluded that 
BsmI and polymorphisms in high linkage disequilibrium (LD) 
with this single-nucleotide polymorphism (SNP) modified the 
risk for relapse in individuals with lower levels (≤50.4 nm/l) of 
serum Vitamin D. We have previously carried out the analysis 
of 38 common SNPs in relation to melanoma risk (59). Here, we 
investigate their influence on prognosis. To our knowledge, this 
is the first study addressing the effect of a comprehensive set of 
common VDR polymorphisms on melanoma-specific survival in 
a large population-based study.
Materials and methods
Study subjects
Subjects were recruited between 1998 and 2003 into an international mul-
ticenter population-based study of melanoma, the Genes, Environment 
and Melanoma (GEM) Study. The GEM study population, identified in 
eight population-based registries in Australia, Canada, Italy and the USA, 
and one hospital center in the USA, consists of incident single primary 
melanoma cases (n  =  2361) and incident multiple primary melanoma 
cases (n = 1205). Details of the study design and its rationale have been 
published (60,61). The human research oversight committees at each of 
the GEM study sites approved the study protocol. The sites include those 
at the British Columbia Cancer Agency, Vancouver, British Columbia, 
Canada; Cancer Care Ontario, Toronto, Ontario, Canada; Center for Cancer 
Prevention, Turin, Italy; Memorial Sloan Kettering Cancer Center, New 
York, NY; Menzies Cancer Center, Hobart, Tasmania, Australia; University 
of California, Irvine, CA; University of Michigan, Ann Arbor, MI; University 
of North Carolina, Chapel Hill, NC and University of Sydney, Sydney, New 
South Wales, Australia. All the participants signed written informed 
consent.
Outcomes
A thorough search for deaths and their causes was completed at each 
ascertainment center, and the information on vital status (alive at the 
end of follow-up, dead of disease or dead of other causes) was obtained 
for all the participating individuals with melanoma. Patient follow-up for 
vital status ended on 31 December 2007 in all centers, except for British 
Columbia and Turin, where follow-up period ended on 31 December 2008. 
Date and cause of death were obtained from National Death Indexes 
(62,63), cancer registries and municipal records. Cases were considered 
alive if not in the National Death Index.
Genotyping
All aspects of the genotyping pipeline in GEM including selection of VDR 
SNPs, DNA extraction, genotyping details and quality control procedures 
have been described (59). Briefly, we included SNPs with known or sus-
pected impact on the transcription, stability and/or activity of the VDR; 
SNPs reported as significant in other association studies and the minimal 
set of tagging SNPs described among Caucasians by others (64,65) with 
minor allele frequency >10% in Caucasians. Germline (buccal) DNA was 
genotyped with the Sequenom MassARRAY iPLEX genotyping Platform 
(Sequenom, San Diego, CA, currently Agena Bioscience) to test 36 SNPs 
and with pyrosequencing and melting temperature analysis to test 2 
SNPs, for a total of 38 SNPs (59). Standard quality control procedures 
were implemented and included, among others, the use of internal labo-
ratory controls and 5–10% randomly selected repeats. A plate containing 
discordant results for at least one pair of duplicate samples or internal 
controls was newly assayed, thus complete concordance between repli-
cas was achieved. Assays were considered optimal according to degree of 
clustering, specificity and reproducibility. Hardy–Weinberg equilibrium 
was calculated to identify major genotyping issues (59). However, as 
the cohort consists solely of cases with the disease absence of Hardy–
Weinberg equilibrium could be due to the SNP conferring risk for the 
disease. We also evaluated the potential functional relevance of the 
investigated VDR SNPs in relation to known and predicted regulatory 
elements in the intergenic regions of the human genome. Known and 
predicted regulatory DNA elements including regions of deoxyribonucle-
ase hypersensitivity, binding sites of transcription factors and promoter 
regions have been biochemically characterized to regulate transcription 
by accessing publicly available data using the RegulomeDB as a source 
of information from the public Gene Expression Omnibus database, the 
ENCODE project, and published literature (66).
Abbreviations 
GEM Genes, Environment, and Melanoma 
HR hazard ratio 
LD linkage disequilibrium 
SNP single-nucleotide polymorphism
VDR vitamin D receptor 
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Analysis of survival outcomes
Survival outcomes were calculated for each SNP using competing risk 
models. The endpoint was either date of death or end of follow-up for the 
censored patients. Patients were censored at the time of death from other 
(non-melanoma) causes as recorded in the vital records. There was no loss 
of follow-up based on the study design. Since the parent study involved 
population-based ascertainment of incident single primary melanoma 
cases and incident multiple primary melanoma cases, survival time was 
accumulated from the diagnosis date of the index lesion; this is the date 
of the first primary for patients with single primary lesions and the date of 
the index (more recent) lesion for patients with multiple primaries.
Analysis of associations between VDR genotypes 
and survival
Proportionality was evaluated for each SNP using a competing risk model 
in which the constancy of the time dependency of the survival rate ratio 
of wild-type versus non-wild-type genotypes was tested individually. For 
each SNP, we arbitrarily refer to the least frequently occurring allele as 
the variant allele, and the most common allele as the referent allele. Log-
additive trend tests were used to assess the statistical significance of the 
per allele hazard ratios (HRs), which represents the risk associated with 
carriage of each additional variant allele.
We found no differences in the effects of VDR SNPs on survival by pri-
mary status (single versus multiple primary melanoma), and therefore the 
associations of VDR SNPs with survival were examined in all patients in 
order to improve precision, while adjusting for primary status as described 
elsewhere (67,68).
Our primary analytic strategy involved analyses in which we tested 
the associations of the SNPs with melanoma-specific survival adjusted 
for factors that have the potential to confound the association of VDR 
genotype with survival. To account for the competing risk of death from 
other causes, we performed proportional subdistribution hazards regres-
sion models according to ref. (69) to assess the effects of covariates on the 
subdistribution hazard for death as a result of melanoma. We adjusted for 
age, sex, anatomic site of the primary and study design variables (study 
center, case–control status and a time-dependent covariate for single pri-
mary melanomas who developed subsequent melanoma) in our analy-
sis. For those who developed multiple primary lesions, the anatomic site 
and pathological characteristics of the deepest tumor were used in the 
analysis. It is biologically plausible that Vitamin D may act via compo-
nents of tumor stage; however, tumor stage was missing in one-third of 
our cases. Instead, Breslow thickness, which was highly correlated with 
tumor stage (r2 = 0.91), was included as a surrogate for tumor stage. We 
tested for potential associations between VDR SNPs and Breslow thick-
ness using Spearman rank correlation tests and explored the associations 
between VDR SNPs and melanoma death in a second multivariable model 
that included Breslow thickness. We also tested the associations between 
VDR SNPs and other known markers of melanoma progression including 
mitosis and ulceration, using the Wilcoxon Rank Sum test for participants 
without missing data for these variables.
We employed the Monte Carlo approach to adjust for multiple testing 
(70,71). The joint distribution of the test statistics for the SNPs was first 
evaluated by an efficient Monte Carlo procedure, and the joint distribution 
was then used to determine the multiple-testing adjusted significance 
threshold. This approach properly accounts for the LD between SNPs and 
is slightly less conservative than the traditional Bonferroni correction 
method.
Analysis of associations between haplotypes and 
survival
We investigated the effect of haplotypes within blocks 1–6 (Supplementary 
Figure S1, available at Carcinogenesis Online) as determined by Haploview 
(72). We also investigated the previously published haplotype rs11568820–
rs2228570–rs144410 (Cdx2–FokI–BsmI) (47,48) by using PHASE version 2.1 
software to impute haplotype frequencies (73,74). Each GEM patient was 
assigned the haplotype with the highest probability and patients in these 
haplotype groupings were compared collectively with respect to survival.
Analyses were performed using SAS statistical software version 9.2 
(SAS Institute, Cary, NC). The competing risk models was implemented 
using the mstate package in R statistical software (Vienna, Austria) (75), 
and the Monte Carlo procedure was implemented using the R scripts pro-
vided by the He et al. (70). All tests were two-tailed and P values of <0.05 
were deemed statistically significant, unless multiple comparisons were 
considered.
Results
There were 3566 cases consisting of 1562 females and 2004 
males. During the follow-up period (range 0.4–10.6  years, 
median 7.6 years), there were 562 (15.7%) deaths, of which 254 
(7.1%) were due to melanoma. Of these 254 deaths, 103 (40.6%) 
occurred following a diagnosis of second or higher order mela-
noma. Adjusted risks of death from melanoma for host and 
tumor characteristics of GEM study participants are presented 
in Table  1. Risk for dying from melanoma was increased in 
older individuals, men, individuals with thicker tumors and 
those with melanomas on the head and neck. No differences 
in survival were observed comparing cases with single primary 
to those with multiple primary melanoma (HR 0.99, 95% con-
fidence interval: 0.75–1.31, P  =  0.95). When including Breslow 
thickness of the deepest primary melanoma in the model, age 
Table 1. Effect of demographic and clinicopathologic characteristics 
of melanoma patients in the GEM study on disease-specific mortality
Variable N (%) N events HRa 95% CIa P valuea
Gender
 Male 2004 (56.2) 183 1 <0.001
 Female 1562 (43.8) 71 0.57 0.43–0.76
Age at diagnosis
 Continuous — 1.03 1.02–1.04 <0.001
Site
 Head/neck 575 (16.1) 76 1 <0.001
 Trunk/pelvis 1580 (44.3) 107 0.55 0.41–0.75
 Arms 665 (18.7) 34 0.47 0.31–0.70
 Legs 746 (20.9) 37 0.51 0.34–0.78
Histology
 SSM 2294 (64.3) 105 1 <0.001
 NM 332 (9.3) 70 4.34 3.19–5.92
 LM 364 (10.2) 18 0.84 0.51–1.40
 NOS 495 (13.9) 40 1.83 1.26–2.67
 Other 81 (2.3) 21 5.20 3.23–8.36
Breslow thickness
 0.01–1.00 2223 (62.3) 44 1 <0.001
 1.01–2.00 723 (20.3) 79 5.55 3.83–8.04
 2.01–4.00 359 (10.1) 75 10.44 7.16–15.22
 >4.00 175 (4.9) 52 15.50 10.32–23.29
 Missing 86 (2.4) 4
Ulceration
 Absent 2475 (69.4) 140 1 <0.001
 Present 262 (7.4) 69 4.81 3.58–6.47
 Missing 829 (23.2) 45
Mitoses
 Absent 1520 (42.6) 41 1 <0.001
 Present 1227 (34.4) 169 5.05 3.59–7.11
 Missing 819 (23.0) 44
Patients who entered the study with single primary melanoma and developed 
a subsequent melanoma were treated as time dependent. LM, lentigo maligna; 
NM, nodular melanoma; NOS, not otherwise specified; SSM, superficial spread-
ing melanoma.
aAdjusted for study center, presence of multiple primary melanomas, time-de-
pendent crossover status (patients who entered the study with single primary 
melanoma and developed a subsequent melanoma) and age at diagnosis of the 
first primary melanoma and sex.
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and anatomic site remained significantly associated with mela-
noma death adjusted for all study design features.
VDR SNPs and tumor characteristics
There was little evidence of association between the 38 VDR SNPs 
and tumor markers of progression. Only one SNP (rs1989969) 
was associated with tumor thickness (P = 0.04), but this SNP was 
not associated with survival. No significant associations were 
found between any of the studied SNPs with either ulcerations 
or mitosis (Supplementary Table S1, available at Carcinogenesis 
Online).
VDR SNPs and melanoma-specific death
All VDR SNP genotype frequencies were in Hardy–Weinberg 
equilibrium. Table  2 shows the per allele subdistribution HRs 
for each individual SNP for melanoma-specific death in Fine 
and Gray models for the subdistribution of competing risks. 
With few exceptions, the models were observed to satisfy the 
proportional hazards assumption. Individually, SNPs rs7299460, 
rs3782905, rs2239182, rs12370156, rs2238140, rs7305032, 
rs1544410 (BsmI) and rs731236 (TaqI) were significantly asso-
ciated with melanoma-specific survival after accounting for 
competing risk of death from other causes and after adjusting 
for age at first diagnosis, sex, anatomic site and study design 
features (Table  2). Some of the SNPs are in strong LD. The LD 
plot showing all 38 SNPs is provided in Supplementary Figure S1, 
available at Carcinogenesis Online. The SNP with the most statis-
tically significant association exceeded the Monte Carlo multi-
ple comparison threshold (rs2239182, P value = 0.0018). Publicly 
available data reveal that rs2239182 overlaps with the binding 
site of the FOXA1 protein and that this SNP affects VDR expres-
sion (76). When analyses were repeated additionally adjusting 
for tumor thickness, five SNPs were significantly associated with 
melanoma death (rs4760674, rs2239182, rs7305032, rs1544410 
and rs731236), and one SNP had a borderline significant associa-
tion (rs2189480); in total, four SNPs overlapped with those in our 
primary analysis, including rs2239182.
VDR haplotypes and melanoma-specific survival
We investigated the association between VDR haplotypes 
defined by the six haplotype blocks (Supplementary Figure S1, 
available at Carcinogenesis Online) and melanoma-specific death 
adjusting for competing risk of death from other causes. The 
haplotype C–C–G formed by rs12370156–rs2238140–rs7305032 
was associated with death of melanoma after adjusting for 
covariates (per haplotype HR: 1.22, 95% confidence interval: 
1.02–1.45), and the global test of association was significant 
(P  =  0.04) (Supplementary Table S2, available at Carcinogenesis 
Online). We also investigated the association between previ-
ously published rs11568820/Cdx-2, rs2228570/FokI and rs144410/
BsmI allelotypes and melanoma-specific death and found no 
significant associations (Supplementary Table S3, available at 
Carcinogenesis Online).
Discussion
In this comprehensive evaluation of common VDR polymor-
phisms in relation to melanoma survival in a large cohort of 
melanoma cases, we found nominally significant associa-
tions between eight SNPs mostly located on the coding region 
[rs7299460, rs3782905, rs2239182, rs12370156, rs2238140, 
rs7305032, rs1544410 (BsmI) and rs731236 (TaqI)] and mela-
noma-specific death, and one SNP (rs2239182) remained signifi-
cant after adjustment for multiple testing. Rs2239182 is known 
to have functional importance, and thus, our results are bio-
logically plausible considering that vitamin D exerts a variety 
of tumor suppression effects through its receptor (29–34), VDR 
expression has been linked to improved survival in other can-
cers (38–41) and to melanoma progression (42,43) and frequent 
polymorphisms can, in principle, have a modest to moderate 
effect on its function.
None of the SNPs that we found to be associated with mela-
noma-specific survival were associated with Breslow thickness, 
ulceration or mitosis, indicating that the possible effect of VDR 
SNPs on survival does not occur directly through these tumor 
features. Considering the wide distribution of VDR throughout 
the body and that its ligand (vitamin D) has a plethora of effects 
including, among many others the regulation of adaptive and 
innate immune system (77,78), it is possible to propose that VDR 
modulates the tumor microenvironment and exerts its effect 
though other (non-melanoma) cell types (79).
There is limited published data on the relationship between 
VDR polymorphisms and outcomes in melanoma patients, and 
other investigations included small cohorts, few polymorphisms 
and used tumor thickness (80–83), metastasis (80) or relapse and 
overall survival as endpoints (36). Among these, the largest study 
conducted by Newton-Bishop et al. (36), investigated five (Cdx-2, 
FokI, BsmI, TaqI and rs4516035) of the 38 SNPs reported here and 1 
SNP (rs7975232) that we did not genotype in a prospective study of 
872 individuals with melanoma. Their study found no main effect 
of VDR genotypes on relapse or overall survival, although the 
authors found increased risk for relapse in carriers of the BsmI 
A allele in patients with low serum vitamin D levels (36). Similar 
to Newton-Bishop et al., we found no effect for FokI (rs2228570). In 
contrast, our study found the BsmI A allele and TaqI ‘t’(C) allele to 
be protective with regard to melanoma death (Table 2). It is pos-
sible that the results differ between these two studies due to the 
study populations with different proportion of cases with thin 
(<1 mm) tumors (62.3% versus 36.3%), follow-up time (7.6 versus 
4.7 years), selected endpoint and statistical power. As we did not 
measure circulating levels of vitamin D, it is not possible to assess 
its potential modifying effect on genetic associations in the GEM 
study. Newton-Bishop et al. did not genotype the functional SNP 
with the strongest association in GEM, rs2239182.
In a prior study of 316 melanoma cases and VDR in rela-
tion to Breslow tumor thickness as outcome, Hutchinson et al. 
(81) reported that the combined TaqI and FokI variant alleles 
‘ttff’ (CCTT) increased the risk for having tumors >1.5 mm. 
Santonocito et al. (82) investigated the effect of BsmI, FokI and 
rs4516035 (A-1012G) in 100 cases and reported a significant asso-
ciation between the BsmI variant ‘b’ (G) and tumors >1.5 mm. 
In contrast, two studies, one of 1001 melanoma cases (84), that 
investigated Cdx-2, FokI, BsmI, ApaI, rs4516035 and TaqI, and 
another study that investigated four VDR SNPs (TaqI, rs757343, 
rs2107301 and rs7975232) in 305 melanoma cases (83) found no 
associations with Breslow thickness, findings in agreement with 
the present study.
The intronic BsmI is one of the most studied VDR SNPs, 
although the observed functional impact of this polymorphism 
is not consistent across investigations (45). This SNP is in high 
LD with TaqI (rs731236), a silent SNP that localizes to a nucleo-
tide conserved across species, and like BsmI, is also inversely 
associated with death from melanoma in this study.
To the best of our knowledge, several of the significant 
SNPs found in our study (coding region rs3782905, rs2239182, 
rs12370156, rs2238140, rs7305032 and promoter region rs7299460) 
have not been previously reported in relation to melanoma sur-
vival or Breslow thickness as the outcomes. The most significant 
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Table 2. Subdistribution hazard ratios according to VDR variants for death of melanoma in GEM accounting for competing risk of death from 
other causes
Relative 5′ > 3′ 
position, RefSeq Chr12: position Genotype
Total N (N 
events)
Per allele adjusted 
sHR (95% CI)a
Trend P 
valuea
Per allele adjusted 
sHR (95% CI)b
Trend P 
valueb
Promoter region
1 rs2071358 46652716 CC 2423 (178)
CA 965 (64)
AA 121 (4) 0.85 (0.67–1.07) 0.170 0.81 (0.63–1.03) 0.111
2 rs10875712 46649520 GG 1419 (103)
GC 1587 (98)
CC 493 (45) 1.07 (0.89–1.30) 0.472 1.12 (0.92–1.36) 0.277
3 rs6823 46648679 CC 1102 (78)
CG 1673 (118)
GG 737 (54) 1.03 (0.86–1.23) 0.752 1.06 (0.89–1.28) 0.501
4 rs4760674 46643281 CC 1350 (94)
CA 1634 (107)
AA 541 (48) 1.11 (0.92–1.34) 0.270 1.22 (1.01–1.47) 0.042
5 rs1015390 46630305 CC 2581 (192)
CT 862 (51)
TT 83 (5) 0.81 (0.61–1.07) 0.134 0.84 (0.63–1.12) 0.233
6 rs4237856 46624317 AA 1977 (131)
CA 1279 (97)
CC 230 (17) 1.11 (0.91–1.35) 0.308 1.02 (0.84–1.24) 0.824
7 rs4073729 46623336 CC 2567 (189)
TC 874 (57)
TT 80 (3) 0.82 (0.63–1.07) 0.145 0.84 (0.64–1.11) 0.221
8 rs11168314 46616896 GG 2276 (173)
GA 1067 (69)
AA 164 (8) 0.80 (0.64–1.01) 0.060 0.84 (0.67–1.06) 0.150
9 rs10459217 46602528 TT 2230 (168)
TC 1120 (73)
CC 160 (9) 0.85 (0.68–1.07) 0.166 0.88 (0.69–1.11) 0.280
10 rs11568820 46588812 GG 2193 (164)
Cdx-2 AG 822 (57)
AA 137 (7) 0.85 (0.67–1.09) 0.203 0.88 (0.68–1.12) 0.297
11 rs7139166 46586601 CC 1162 (78)
GC 1616 (108)
GG 682 (55) 1.12 (0.93–1.33) 0.224 1.16 (0.96–1.41) 0.114
12 rs4516035 46586093 TT 1166 (76)
−1012|GATA CT 1661 (117)
CC 687 (54) 1.13 (0.95–1.34) 0.182 1.16 (0.96–1.40) 0.116
13 rs7299460 46582535 CC 1734 (136)
CT 1421 (96)
TT 345 (16) 0.80 (0.66–0.97) 0.021 0.85 (0.70–1.03) 0.091
14 rs11168287 46571681 GG 903 (67)
AG 1710 (120)
AA 882 (59) 0.97 (0.81–1.15) 0.718 1.01 (0.83–1.22) 0.949
15 rs11168284 46569316 AA 1439 (111)
GA 1628 (112)
GG 430 (24) 0.87 (0.72–1.04) 0.134 0.86 (0.71–1.06) 0.154
16 rs10875694 46567927 TT 2454 (176)
TA 978 (68)
AA 119 (7) 0.94 (0.75–1.19) 0.605 0.95 (0.75–1.21) 0.695
17 rs4760648 46566932 CC 1100 (87)
CT 1776 (119)
TT 639 (44) 0.93 (0.77–1.11) 0.398 0.94 (0.77–1.14) 0.528
18 rs2238135 46564457 GG 2024 (147)
GC 1281 (88)
CC 227 (15) 0.95 (0.78–1.17) 0.650 0.96 (0.78–1.18) 0.672
19 rs1989969 46564277 CC 1308 (81)
CT 1667 (124)
TT 565 (46) 1.14 (0.96–1.36) 0.128 1.14 (0.95–1.37) 0.153
Coding region
20 rs2228570 46559162 CC (FF) 1258 (98)
FokI CT (Ff) 1616 (98)
TT (ff) 514 (37) 0.93 (0.76–1.13) 0.467 0.96 (0.77–1.19) 0.682
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Relative 5′ > 3′ 
position, RefSeq Chr12: position Genotype
Total N (N 
events)
Per allele adjusted 
sHR (95% CI)a
Trend P 
valuea
Per allele adjusted 
sHR (95% CI)b
Trend P 
valueb
21 rs11168275 46558542 AA 2029 (152)
GA 1302 (81)
GG 218 (18) 0.97 (0.78–1.20) 0.756 0.96 (0.77–1.20) 0.701
22 rs7974708 46556432 TT 1478 (125)
CT 1637 (96)
CC 412 (30) 0.83 (0.68 – 1.02) 0.078 0.87 (0.70–1.07) 0.176
23 rs3782905 46552434 CC 1603 (132)
CG 1562 (96)
GG 365 (22) 0.80 (0.65–0.98) 0.031 0.84 (0.67–1.04) 0.100
24 rs2189480 46550095 CC 1453 (89)
CA 1575 (117)
AA 471 (38) 1.17 (0.98–1.40) 0.082 1.18 (0.98–1.42) 0.076
25 rs886441 46549231 TT 2297 (157)
CT 1066 (80)
CC 149 (11) 1.09 (0.88–1.36) 0.429 1.06 (0.83–1.34) 0.650
26 rs2239181 46542216 TT 2817 (201)
GT 672 (48)
GG 33 (1) 0.97 (0.73–1.29) 0.821 1.04 (0.77–1.41) 0.788
27 rs2107301 46541837 CC 1842 (125)
CT 1416 (98)
TT 267 (28) 1.18 (0.97–1.44) 0.094 1.10 (0.89–1.35) 0.365
28 rs2239182 46541678 GG 965 (51)
AG 1676 (121)
AA 816 (72) 1.33 (1.12–1.58) 0.001 1.25 (1.05–1.49) 0.013
29 rs12370156 46540400 TT 946 (55)
CT 1708 (126)
CC 866 (69) 1.19 (1.00–1.41) 0.046 1.15 (0.96–1.38) 0.136
30 rs2238140 46538931 TT 944 (54)
CT 1719 (127)
CC 866 (69) 1.19 (1.01–1.42) 0.042 1.15 (0.96–1.39) 0.127
31 rs7305032 46536127 AA 928 (54)
AG 1730 (130)
GG 670 (55) 1.22 (1.02–1.46) 0.028 1.22 (1.01–1.48) 0.042
32 rs1544410 46526102 GG (bb) 1229 (100)
BsmI GA (bB) 1625 (107)
AA (BB) 562 (31) 0.78 (0.65–0.94) 0.008 0.79 (0.64–0.96) 0.017
33 rs731236 46525024 TT (TT) 1263 (105)
TaqI TC (Tt) 1633 (107)
CC (tt) 594 (33) 0.78 (0.65–0.94) 0.010 0.81 (0.67–0.99) 0.037
3′ UTR
34 rs11574139 46521822 AA 3275 (238)
TA 247 (11)
TT 9 (1) 0.70 (0.39–1.26) 0.237 0.67 (0.36–1.24) 0.205
35 rs7965281 46517877 GG 810 (48)
AG 1840 (133)
AA 694 (54) 1.18 (0.97–1.43) 0.098 1.15 (0.94–1.42) 0.171
36 rs2544027 46502796 CC 977 (74)
CT 1664 (118)
TT 892 (58) 0.93 (0.79–1.10) 0.415 0.92 (0.78–1.10) 0.373
37 rs2544028 46502697 TT 1234 (90)
TA 1626 (121)
AA 654 (38) 0.92 (0.78–1.09) 0.323 0.94 (0.79–1.12) 0.468
38 rs2544038 46501500 TT 1112 (82)
CT 1637 (115)
CC 752 (49) 0.94 (0.79–1.11) 0.460 0.93 (0.78–1.11) 0.403
Patients who entered the study with single primary melanoma and developed a subsequent melanoma were treated as time dependent. SNP 
position on Chr12 is shown for the hg19. Statistically significant associations (P < 0.05) are shown in bold. 3′ UTR, 3′ untranslated region; Chr12, 
Chromosome 12; CI, confidence interval; hg19, human genome version 19; N, number; sHR, subdistribution hazard ratio; SNP, single-nucleotide 
polymorphism.
aAdjusted for age at first diagnosis, sex, anatomic site of the deepest primary melanoma and study design features (study center, presence of 
multiple primary melanoma, time-dependent crossovers).
bAdjusted for age at first diagnosis, sex, anatomic site of the deepest primary melanoma, Breslow thickness and study design features (study 
center, presence of multiple primary melanoma, time-dependent crossovers).
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SNP in this study (rs2239182) is located in the coding region of 
the VDR gene. This locus is often found near active regulatory 
elements, and eQTL analysis indicates that rs2239182 affects 
VDR expression in a cis fashion (66,76), which further supports 
our observed association, although future studies will have to 
confirm the direction of the effect in melanoma tumors. SNP 
rs2239182 overlaps with the binding site of the FOXA1 protein. 
Of interest, in a recent whole transcriptome RNA-seq analysis of 
melanoma-derived cell lines, this transcription factor was listed 
in the top cancer-associated category and can interact with 
either transcription factors or cytokines known to be involved 
in the development or progression of other malignancies (85).
We reported previously eight of these VDR SNPs significantly 
associated with melanoma risk (59). When we compared these 
candidate melanoma ‘susceptibility’ SNPs with those found in our 
present analysis of melanoma-specific survival only two overlap: 
rs7305032, associated with worse survival but with lower mela-
noma risk and BsmI, associated with improved survival but higher 
risk of melanoma. An adverse effect on risk allied to improved 
survival and vice versa has also been observed in other studies 
(55,86). It is possible that VDR plays different roles in melanoma 
initiation and in progression (e.g. via tumor suppression versus 
cell migration, inflammation or other processes), depending on 
the cell context and the availability of transcription factors, in 
which case polymorphisms that predict disease outcome might 
be expected to differ from those that predict melanoma risk.
The strengths of our study include its large size that allows 
us to detect relatively small HRs, the population-based nature 
of the study, geographically diverse populations that allow our 
results to be generalized and inclusion of 38 SNPs spanning the 
promoter to the 3′ untranslated region of the gene, which con-
stitutes a more comprehensive coverage of the gene than previ-
ously reported. A limitation of our study is that we did not study 
polymorphisms in other genes involved in the vitamin D path-
way, which might also play a role in melanoma survival.
In conclusion, we found that several SNPs mostly located in 
the coding region of the VDR gene, including a functional SNP 
that exceeded the multiple comparisons threshold, were asso-
ciated with melanoma-specific survival. Although the observed 
genetic effect size is modest, our results provide evidence in sup-
port of the hypothesis that variants in the vitamin D pathway 
may play an important role in melanoma survival. Our finding 
that the SNPs are not associated with Breslow thickness, ulcera-
tion or mitosis, indicates that the mechanism by which VDR 
may exert its effect does not seem driven locally by these tumor 
characteristics. Although an effect on a particular yet undefined 
etiologic melanoma subtype should not be ruled out, it is also 
possible that VDR modulates survival by a systemic mechanism. 
Further studies are needed to confirm our findings and inves-
tigate the role of the vitamin D pathway, including potential 
downstream effectors, in relation to melanoma outcome in the 
context of tumor and host characteristics.
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found at http://carcin.oxfordjournals.org/
Funding
National Cancer Institute [UO183180, CA112524 and CA112524-S1 
to M.B.; CA112243 and CA112243-05S1 to N.T.; P30-CA008748 to 
Memorial Sloan Kettering Cancer Center (MSK)]; Anbinder Fund 
(to MSK Sequenom facility).
Acknowledgements
We wish to thank S.Yoo for her technical assistance with 
the genotyping assays; J.Kanik for assistance with graphics; 
K.Laning, Y.Majoka and F.Ajmeri for assistance with the format-
ting of this manuscript and all the individuals who agreed to 
participate in the study.
The study was conducted by the GEM Study Group. 
Coordinating Center, Memorial Sloan Kettering Cancer Center, 
New York, NY: M.B. (PI, currently at the University of New Mexico), 
C.B.B. (Co-PI), I.O. (Co-investigator), K.J.B. (Dermatopathologist), 
P.R. (Senior Laboratory Technician), H.Parmar (Senior Laboratory 
Technician), A.S.R. (Biostatistician), Y.Xu (Data Analyst). 
University of New Mexico, Albuquerque, NM: M.B. (PI), L.L. 
(Biostatistician), K.White (Laboratory Manager), S.P. (Data 
Manager). Study Centers: The University of Sydney and The 
Cancer Council New South Wales, Sydney, New South Wales, 
Australia: B.K.A. (PI), A.K. (Co-PI), A.E.Cust (Co-investigator); 
Menzies Research Institute, University of Tasmania, Hobart, 
Tasmania, Australia: A.Venn (current PI), T.D. (PI, currently at 
University of Oxford, UK), P.Tucker (Dermatopathologist); British 
Columbia Cancer Research Centre, Vancouver, British Columbia, 
Canada: R.P.G. (PI), D.Kan (Coordinator); Cancer Care Ontario, 
Toronto, Ontario, Canada: L.D.M. (PI), E.Theis (Co-investigator), 
L.From (Dermatopathologist); CPO, Center for Cancer Prevention, 
Torino, Italy: R.Z. (PI), S.R. (Co-PI); University of California, Irvine, 
CA: H.A.-C. (PI), A.Ziogas (Statistician); University of Michigan, 
Ann Arbor, MI: S.B.G. (PI, currently at University of Southern 
California, Los Angeles, CA), T.Johnson (Director of Melanoma 
Program), D.Sturgeon (Co-investigator, joint at USC–University of 
Michigan); University of North Carolina, Chapel Hill, NC: N.E.T. (PI), 
R.C.Millikan (previous PI, deceased), D.W.Ollila (Co-investigator), 
K.Conway (Co-investigator), P.A.Groben (Dermatopathologist), 
S.N.Edmiston (Research Analyst), H.Hao (Laboratory Specialist), 
E.Parrish (Laboratory Specialist), D.C.Gibbs (Research Assistant), 
J.S.Frank (Research Assistant), J.I.Bramson (Research Assistant); 
University of Pennsylvania, Philadelphia, PA: T.R.Rebbeck (PI), 
P.A.K. (Co-investigator, currently at H. Lee Moffitt Cancer Center 
& Research Institute, Tampa, FL); UV data consultants: J.L.Taylor 
and S.Madronich, National Centre for Atmospheric Research, 
Boulder, CO.
Conflict of Interest Statement: None declared. 
References
 1. Howlader, N. et al. SEER Cancer Statistics Review, 1975–2010. National 
Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2010/ 
(April 2013 date last accessed).
 2. Soong, S.J. et al. (2010) Predicting survival outcome of localized mela-
noma: an electronic prediction tool based on the AJCC Melanoma 
Database. Ann. Surg. Oncol., 17, 2006–2014.
 3. de Vries, E. et  al. (2008) Superior survival of females among 10,538 
Dutch melanoma patients is independent of Breslow thickness, histo-
logic type and tumor site. Ann. Oncol., 19, 583–589.
 4. Joosse, A. et al. (2012) Superior outcome of women with stage I/II cuta-
neous melanoma: pooled analysis of four European Organisation for 
Research and Treatment of Cancer phase III trials. J. Clin. Oncol., 30, 
2240–2247.
 5. Lasithiotakis, K. et al. (2008) Age and gender are significant independ-
ent predictors of survival in primary cutaneous melanoma. Cancer, 
112, 1795–1804.
 6. Berwick, M. et al. (2005) Sun exposure and mortality from melanoma. J. 
Natl Cancer Inst., 97, 195–199.
 7. Balch, C.M. et al. (2009) Final version of 2009 AJCC melanoma staging 
and classification. J. Clin. Oncol., 27, 6199–6206.
 8. Davies, J.R. et al. (2014) Inherited variation in the PARP1 gene and sur-
vival from melanoma. Int. J. Cancer, 135, 1625–1633.
I.Orlow et al. | 37
 9. Fang, S. et al. (2015) Association of common genetic polymorphisms 
with melanoma patient IL-12p40 blood levels, risk, and outcomes. J. 
Invest. Dermatol., 135, 2266–2272.
 10. Li, C. et al. (2013) Polymorphisms of nucleotide excision repair genes 
predict melanoma survival. J. Invest. Dermatol., 133, 1813–1821.
 11. Liu, H. et al. (2012) Influence of single nucleotide polymorphisms in the 
MMP1 promoter region on cutaneous melanoma progression. Mela-
noma Res., 22, 169–175.
 12. Park, J.Y. et  al. (2013) Gene variants in angiogenesis and lymphangi-
ogenesis and cutaneous melanoma progression. Cancer Epidemiol. 
Biomarkers Prev., 22, 827–834.
 13. Rendleman, J. et al. (2015) Genetic associations of the interleukin locus 
at 1q32.1 with clinical outcomes of cutaneous melanoma. J. Med. 
Genet., 52, 231–239.
 14. Yin, J. et al. (2015) Genetic variants in Fanconi anemia pathway genes 
BRCA2 and FANCA predict melanoma survival. J. Invest. Dermatol., 135, 
542–550.
 15. Afzal, S. et  al. (2013) Low plasma 25-hydroxyvitamin D and risk of 
tobacco-related cancer. Clin. Chem., 59, 771–780.
 16. Bilinski, K. et al. (2013) Association between 25-hydroxyvitamin D con-
centration and breast cancer risk in an Australian population: an obser-
vational case-control study. Breast Cancer Res. Treat., 137, 599–607.
 17. Chen, P. et al. (2010) Meta-analysis of vitamin D, calcium and the pre-
vention of breast cancer. Breast Cancer Res. Treat., 121, 469–477.
 18. Engel, P. et al. (2011) Joint effects of dietary vitamin D and sun exposure 
on breast cancer risk: results from the French E3N cohort. Cancer Epi-
demiol. Biomarkers Prev., 20, 187–198.
 19. Fang, F. et al. (2011) Prediagnostic plasma vitamin D metabolites and 
mortality among patients with prostate cancer. PLoS One, 6, e18625.
 20. Freedman, D.M. et al. (2007) Prospective study of serum vitamin D and 
cancer mortality in the United States. J. Natl Cancer Inst., 99, 1594–
1602.
 21. Morton, M.L. et  al. (2013) Decreasing 25-hydroxy-vitamin D levels 
account for portion of the effect of increasing body mass index on 
breast cancer mortality. Mol. Nutr. Food Res., 57, 260–266.
 22. Ng, K. et al. (2008) Circulating 25-hydroxyvitamin d levels and survival 
in patients with colorectal cancer. J. Clin. Oncol., 26, 2984–2991.
 23. Ordóñez-Mena, J.M. et al. (2013) Serum 25-hydroxyvitamin d and can-
cer risk in older adults: results from a large German prospective cohort 
study. Cancer Epidemiol. Biomarkers Prev., 22, 905–916.
 24. Pilz, S. et al. (2008) Low serum levels of 25-hydroxyvitamin D predict 
fatal cancer in patients referred to coronary angiography. Cancer Epi-
demiol. Biomarkers Prev., 17, 1228–1233.
 25. Tretli, S. et al. (2009) Association between serum 25(OH)D and death 
from prostate cancer. Br. J. Cancer, 100, 450–454.
 26. Zgaga, L. et al. (2014) Plasma vitamin D concentration influences sur-
vival outcome after a diagnosis of colorectal cancer. J. Clin. Oncol., 32, 
2430–2439.
 27. Zhou, W. et al. (2007) Circulating 25-hydroxyvitamin D levels predict 
survival in early-stage non-small-cell lung cancer patients. J. Clin. 
Oncol., 25, 479–485.
 28. Zhou, W. et al. (2005) Vitamin D is associated with improved survival 
in early-stage non-small cell lung cancer patients. Cancer Epidemiol. 
Biomarkers Prev., 14, 2303–2309.
 29. Hansen, C.M. et al. (1998) Down-regulation of laminin-binding integ-
rins by 1 alpha,25-dihydroxyvitamin D3 in human melanoma cells in 
vitro. Cell Adhes. Commun., 5, 109–120.
 30. Yudoh, K. et al. (1999) 1alpha,25-dihydroxyvitamin D3 inhibits in vitro 
invasiveness through the extracellular matrix and in vivo pulmonary 
metastasis of B16 mouse melanoma. J. Lab. Clin. Med., 133, 120–128.
 31. Danielsson, C. et al. (1998) Differential apoptotic response of human 
melanoma cells to 1 alpha,25-dihydroxyvitamin D3 and its analogues. 
Cell Death Differ., 5, 946–952.
 32. Eisman, J.A. et al. (1987) Suppression of in vivo growth of human cancer 
solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res., 47, 21–25.
 33. Evans, S.R. et al. (1996) Vitamin D receptor and growth inhibition by 
1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines. J. 
Surg. Res., 61, 127–133.
 34. Ishibashi, M. et  al. (2012) Antiproliferative and apoptosis-inducing 
effects of lipophilic vitamins on human melanoma A375 cells in vitro. 
Biol. Pharm. Bull., 35, 10–17.
 35. Moan, J. et al. (2008) Addressing the health benefits and risks, involving 
vitamin D or skin cancer, of increased sun exposure. Proc. Natl Acad. 
Sci. USA, 105, 668–673.
 36. Newton-Bishop, J.A. et  al. (2009) Serum 25-hydroxyvitamin D3 levels 
are associated with Breslow thickness at presentation and survival 
from melanoma. J. Clin. Oncol., 27, 5439–5444.
 37. Rosso, S. et al. (2008) Sun exposure prior to diagnosis is associated with 
improved survival in melanoma patients: results from a long-term 
follow-up study of Italian patients. Eur. J. Cancer, 44, 1275–1281.
 38. Kim, S.H. et al. (2012) Characterization of vitamin D receptor (VDR) in 
lung adenocarcinoma. Lung Cancer, 77, 265–271.
 39. Srinivasan, M. et  al. (2011) Nuclear vitamin D receptor expression is 
associated with improved survival in non-small cell lung cancer. J. 
Steroid Biochem. Mol. Biol., 123, 30–36.
 40. Berger, U. et al. (1991) Immunocytochemical determination of estrogen 
receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 recep-
tor in breast cancer and relationship to prognosis. Cancer Res., 51, 
239–244.
 41. Ditsch, N. et  al. (2012) The association between vitamin D receptor 
expression and prolonged overall survival in breast cancer. J. Histo-
chem. Cytochem., 60, 121–129.
 42. Brozyna, A.A. et al. (2011) Expression of vitamin D receptor decreases 
during progression of pigmented skin lesions. Hum. Pathol., 42, 618–
631.
 43. Brozyna, A.A. et  al. (2014) Decreased VDR expression in cutaneous 
melanomas as marker of tumor progression: new data and analyses. 
Anticancer Res., 34, 2735–2743.
 44. Essa, S. et al. (2012) Signature of VDR miRNAs and epigenetic modula-
tion of vitamin D signaling in melanoma cell lines. Anticancer Res., 32, 
383–389.
 45. Uitterlinden, A.G. et al. (2004) Genetics and biology of vitamin D recep-
tor polymorphisms. Gene, 338, 143–156.
 46. Lundin, A.C. et al. (1999) Association of breast cancer progression with 
a vitamin D receptor gene polymorphism. South-East Sweden Breast 
Cancer Group. Cancer Res., 59, 2332–2334.
 47. Heist, R.S. et al. (2008) Circulating 25-hydroxyvitamin D, VDR polymor-
phisms, and survival in advanced non-small-cell lung cancer. J. Clin. 
Oncol., 26, 5596–5602.
 48. Zhou, W. et al. (2006) Polymorphisms of vitamin D receptor and sur-
vival in early-stage non-small cell lung cancer patients. Cancer Epide-
miol. Biomarkers Prev., 15, 2239–2245.
 49. Obara, W. et  al. (2007) Vitamin D receptor gene polymorphisms are 
associated with increased risk and progression of renal cell carcinoma 
in a Japanese population. Int. J. Urol., 14, 483–487.
 50. Tamez, S. et al. (2009) Vitamin D receptor polymorphisms and progno-
sis of patients with epithelial ovarian cancer. Br. J. Cancer, 101, 1957–
1960.
 51. Holt, S.K. et al. (2010) Vitamin D pathway gene variants and prostate 
cancer prognosis. Prostate, 70, 1448–1460.
 52. Shui, I.M. et al. (2012) Vitamin D-related genetic variation, plasma vita-
min D, and risk of lethal prostate cancer: a prospective nested case-
control study. J. Natl. Cancer Inst., 104, 690–699.
 53. Hama, T. et al. (2011) Prognostic significance of vitamin D receptor pol-
ymorphisms in head and neck squamous cell carcinoma. PLoS One, 6, 
e29634.
 54. Zeljic, K. et al. (2012) Vitamin D receptor, CYP27B1 and CYP24A1 genes 
polymorphisms association with oral cancer risk and survival. J. Oral 
Pathol. Med., 41, 779–787.
 55. Anic, G.M. et  al. (2012) An exploratory analysis of common genetic 
variants in the vitamin D pathway including genome-wide associated 
variants in relation to glioma risk and outcome. Cancer Causes Con-
trol, 23, 1443–1449.
 56. Fedirko, V. et  al. (2012) Prediagnostic 25-hydroxyvitamin D, VDR and 
CASR polymorphisms, and survival in patients with colorectal cancer 
in western European populations. Cancer Epidemiol. Biomarkers Prev., 
21, 582–593.
 57. Goode, E.L. et al. (2002) Effect of germ-line genetic variation on breast 
cancer survival in a population-based study. Cancer Res., 62, 3052–3057.
 58. Perna, L. et  al. (2013) Vitamin D receptor genotype rs731236 (Taq1) 
and breast cancer prognosis. Cancer Epidemiol. Biomarkers Prev., 22, 
437–442.
38 | Carcinogenesis, 2016, Vol. 37, No. 1
 59. Orlow, I. et  al. (2012) Vitamin D receptor polymorphisms in patients 
with cutaneous melanoma. Int. J. Cancer, 130, 405–418.
 60. Begg, C.B. et al. (2006) A design for cancer case-control studies using 
only incident cases: experience with the GEM study of melanoma. Int. 
J. Epidemiol., 35, 756–764.
 61. Berwick, M. et al. (2006) The prevalence of CDKN2A germ-line muta-
tions and relative risk for cutaneous malignant melanoma: an interna-
tional population-based study. Cancer Epidemiol. Biomarkers Prev., 15, 
1520–1525.
 62. Fillenbaum, G.G. et al. (2009) Identifying a national death index match. 
Am. J. Epidemiol., 170, 515–518.
 63. Sathiakumar, N. et al. (1998) Using the National Death Index to obtain 
underlying cause of death codes. J. Occup. Environ. Med., 40, 808–813.
 64. Fang, Y. et al. (2005) Promoter and 3′-untranslated-region haplotypes 
in the vitamin d receptor gene predispose to osteoporotic fracture: the 
Rotterdam study. Am. J. Hum. Genet., 77, 807–823.
 65. Nejentsev, S. et al. (2004) Comparative high-resolution analysis of link-
age disequilibrium and tag single nucleotide polymorphisms between 
populations in the vitamin D receptor gene. Hum. Mol. Genet., 13, 
1633–1639.
 66. Boyle, A.P. et al. (2012) Annotation of functional variation in personal 
genomes using RegulomeDB. Genome Res., 22, 1790–1797.
 67. Thomas, N.E. et al. (2013) Tumor-infiltrating lymphocyte grade in pri-
mary melanomas is independently associated with melanoma-specific 
survival in the population-based genes, environment and melanoma 
study. J. Clin. Oncol., 31, 4252–4259.
 68. Thomas, N.E. et  al. (2014) Comparison of clinicopathologic features 
and survival of histopathologically amelanotic and pigmented mela-
nomas: a population-based study. JAMA Dermatol., 150, 1306–1314.
 69. Fine, J.P. et al. (1999) A proportional hazards model for the subdistribu-
tion of a competing risk. J. Am. Stat. Assoc., 94, 496–509.
 70. He, Q. et al. (2013) A general framework for association tests with mul-
tivariate traits in large-scale genomics studies. Genet. Epidemiol., 37, 
759–767.
 71. Lin, D.Y. (2005) An efficient Monte Carlo approach to assessing statisti-
cal significance in genomic studies. Bioinformatics, 21, 781–787.
 72. Barrett, J.C. et al. (2005) Haploview: analysis and visualization of LD and 
haplotype maps. Bioinformatics, 21, 263–265.
 73. Stephens, M. et al. (2005) Accounting for decay of linkage disequilib-
rium in haplotype inference and missing-data imputation. Am. J. Hum. 
Genet., 76, 449–462.
 74. Stephens, M. et al. (2001) A new statistical method for haplotype recon-
struction from population data. Am. J. Hum. Genet., 68, 978–989.
 75. R Core Team. R: A Language and Environment for Statistical Comput-
ing. R Foundation for Statistical Computing, Vienna, Austria. http://
www.R-project.org/ (September 2015, date last accessed).
 76. Schadt, E.E. et  al. (2008) Mapping the genetic architecture of gene 
expression in human liver. PLoS Biol., 6, e107.
 77. Mora, J.R. et al. (2008) Vitamin effects on the immune system: vitamins 
A and D take centre stage. Nat. Rev. Immunol., 8, 685–698.
 78. Trochoutsou, A.I. et  al. (2015) Vitamin-D in the immune system: 
genomic and non-genomic actions. Mini Rev. Med. Chem., 15, 953–963.
 79. Halsall, J.A. et al. (2009) The unfavorable effect of the A allele of the 
vitamin D receptor promoter polymorphism A-1012G has different 
mechanisms related to susceptibility and outcome of malignant mela-
noma. Dermatoendocrinology, 1, 54–57.
 80. Halsall, J.A. et  al. (2004) A novel polymorphism in the 1A promoter 
region of the vitamin D receptor is associated with altered susceptibil-
ity and prognosis in malignant melanoma. Br. J. Cancer, 91, 765–770.
 81. Hutchinson, P.E. et  al. (2000) Vitamin D receptor polymorphisms are 
associated with altered prognosis in patients with malignant mela-
noma. Clin. Cancer Res., 6, 498–504.
 82. Santonocito, C. et al. (2007) Association between cutaneous melanoma, 
Breslow thickness and vitamin D receptor BsmI polymorphism. Br. 
J. Dermatol., 156, 277–282.
 83. Schäfer, A. et al. (2012) No association of vitamin D metabolism-related 
polymorphisms and melanoma risk as well as melanoma prognosis: a 
case-control study. Arch. Dermatol. Res., 304, 353–361.
 84. Randerson-Moor, J.A. et  al. (2009) Vitamin D receptor gene polymor-
phisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-
control comparisons and a meta-analysis of published VDR data. Eur. 
J. Cancer, 45, 3271–3281.
 85. Zhao, H. et al. (2014) Whole transcriptome RNA-seq analysis: tumori-
genesis and metastasis of melanoma. Gene, 548, 234–243.
 86. Fasching, P.A. et al. (2012) The role of genetic breast cancer susceptibil-
ity variants as prognostic factors. Hum. Mol. Genet., 21, 3926–3939.
